Research programme: cardiovascular disorders therapy - DURECT

Drug Profile

Research programme: cardiovascular disorders therapy - DURECT

Alternative Names: Cardiovascular disorders therapy research programme - DURECT

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator DURECT Corporation
  • Class Growth factors
  • Mechanism of Action Angiogenesis inducing agents; Growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 18 Dec 2015 Preclinical development for Cardiovascular disorders is ongoing in USA
  • 07 Dec 2004 Preclinical trials in Cardiovascular disorders in Netherlands (Parenteral)
  • 07 Dec 2004 Preclinical trials in Cardiovascular disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top